Foresite Capital Management IV, LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Foresite Capital Management IV, LLC reported 6 stock positions worth $182.6 million. Its top holding was Pharvaris (PHVS) at 65.3% of the portfolio, followed by Cytokinetics (CYTK, 13.8%) and Maze Therapeutics (MAZE, 7.4%). Compared with Q2 2025, it opened 1 new position, sold out of 1, added to 1 and reduced 1. The biggest buy was a new position in Cytokinetics (CYTK) and the biggest sale Maze Therapeutics (MAZE, shares −75%).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0001704132
- Portfolio Value
- $182.6M (Q3 2025)
- SEC Filing
- 0001104659-25-112500 ↗ filed Nov 14, 2025
Holdings Value
Holdings 6 stocks · $182.6M
| PHVS Pharvaris NV | 65.29% | 4,778,581 | $119.2M | Add +8.3% |
| CYTK Cytokinetics Inc. | 13.79% | 458,295 | $25.2M | New |
| MAZE Maze Therapeutics Inc. | 7.42% | 522,657 | $13.6M | Reduce -75.3% |
| LYEL Lyell Immunopharma Inc. | 7.12% | 800,399 | $13.0M | No change |
| XENE Xenon Pharmaceuticals Inc. | 3.52% | 160,000 | $6.4M | No change |
| RLAY Relay Therapeutics Inc. | 2.86% | 1,000,000 | $5.2M | No change |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $290.2M | PHVS, CYTK, EIKN, RLAY, XENE |
| Q1 2026 | 8 | $237.1M | PHVS, CYTK, EIKN, LYEL, RLAY |
| Q4 2025 | 7 | $229.7M | PHVS, CYTK, LYEL, MAZE, RLAY |
| Q3 2025 | 6 | $182.6M | PHVS, CYTK, MAZE, LYEL, XENE |
| Q2 2025 | 6 | $123.8M | PHVS, MAZE, LYEL, XENE, KURA |
| Q1 2025 | 5 | $111.1M | PHVS, MAZE, LYEL, KURA, RLAY |
| Q4 2024 | 4 | $108.8M | PHVS, KURA, LYEL, RLAY |
| Q3 2024 | 5 | $153.0M | PHVS, KURA, SNDX, LYEL, RLAY |
| Q2 2024 | 4 | $148.8M | PHVS, KURA, SNDX, LYEL |
| Q1 2024 | 5 | $197.9M | PHVS, KURA, KNTE, SNDX, LYEL |